Is Colgate-Palmolive (CL) a risky stock?
As of July 21, 2026, Clavix grades Colgate-Palmolive (CL) B for risk, a composite score of 73 out of 100 on an A+ to F scale, which puts CL in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind CL's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how CL scores on each, as of July 21, 2026.
What's moving CL's risk right now
Company-specific signals Clavix flags behind CL's current grade, drawn from recent news and filings as of July 21, 2026.
Colgate-Palmolive will webcast its Q2 2026 earnings call on July 31 at 8:30 a.m. ET. Separately, Calamos Advisors raised its stake by 4.8% in Q1, per its latest 13F, now holding about $25.9 million in shares.
UBS lifted its price target on Colgate to $106, signaling stronger confidence in the stock's near-term returns. The move points to UBS seeing recent business trends as justifying a higher fair value.
JPMorgan raised its price target for Colgate, framing the change as a bullish outlook on the stock. The bank's analysts expect meaningful upside from the prior target and see Colgate outperforming its peers.
What a B grade means
On the Clavix A+ to F scale, CL's composite of 73 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell CL or any security. Grades are risk indicators, not predictions of return. Data may be delayed.